FDA WARNING_LETTER - Cosmetic Manufacturers (Aust) Pty Ltd. - April 08, 2025

The FDA issued a Warning Letter to Cosmetic Manufacturers Pty Ltd. on February 6, 2026, following an inspection of their Helensvale, Queensland facility from March 31 to April 8, 2025. The letter details significant violations of Current Good Manufacturing Practice (CGMP) regulations for finished pharmaceuticals, classifying their drug products as adulterated under the Federal Food, Drug, and Cosmetic Act.

Key violations include the firm"s failure to adequately test drug products for identity, strength, and critical quality attributes prior to release. Laboratory controls were deemed insufficient, lacking scientifically sound specifications and appropriate test procedures, particularly concerning water for pharmaceutical use and microbiological suitability. The FDA also cited inadequate written procedures for production and process control, specifically identifying issues with manufacturing process validation and environmental monitoring. Lastly, equipment used in manufacturing was not demonstrated to be suitable for its intended use, with deficiencies in filler machine qualification and cleaning validation.

The company has ceased drug production for the U.S. market, acknowledging this commitment. Required actions include a comprehensive assessment and remediation of laboratory practices, updated specifications, and a plan for testing reserve samples. The FDA demands improved process validation, equipment qualification, and cleaning validation programs. Cosmetic Manufacturers must address all deficiencies, provide a detailed response within 15 working days, and notify the FDA before resuming any drug manufacturing operations for the U.S. market to demonstrate sustained CGMP compliance. Failure to comply may lead to continued refusal of import.